Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637501 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines.
- Active
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT06637501: Active Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines.
NCT06637501 is a Phase 2 study of Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 94 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06637501, a Phase 2 study of Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by BeOne Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
Primary Outcome
Best CR/CRi rate per the Independent Review Committee (IRC) response assessment using the 2018 International Workshop on Chronic Lymphocytic Leukemia guidelines with modification for treatment-related lymphocytosis for participants with CLL
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Sonrotoclax
Study Locations (20)
Other
- Centro de Pesquisas Oncologicas Cepon - Florianópolis
- Hospital de Clinicas de Porto Alegre - Porto AlegreRS
- Instituto Dor de Pesquisa E Ensino Sao Paulo - São Paulo
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein - São Paulo
Nebraska
- Nebraska Cancer Specialists (Satellite Site) - Omaha
- Nebraska Cancer Specialists - Omaha
- University of Nebraska Medical Center - Omaha
Texas
- Texas Oncology Dfw - Dallas
- Texas Oncology Tyler - Tyler
Jiangsu
- The First Peoples Hospital of Changzhou - Changzhou
- Jiangsu Province Hospital - Nanjing
Florida
- Cleveland Clinic Florida - Weston
Georgia
- Northwest Georgia Oncology Centers Marietta - Marietta
Illinois
- Illinois Cancer Specialists (Niles) Usor - Niles
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What the registry record for NCT06637501 still lists
NCT06637501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT06637501 names 20 study sites across 13 states, led by Other, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT06637501 about?
NCT06637501 is a clinical study titled "A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia". The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubr...
What is the current status of trial NCT06637501?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2024-11-14. Estimated completion is 2029-09.
What conditions does trial NCT06637501 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT06637501?
The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT06637501?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06637501 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06637501's enrollment target sits among peer trials
94 67th of 187 higher than 121 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI